Condition: HER2-Expressing Solid Tumors · Sponsor: Myeloid Therapeutics
This clinical trial is designed to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of MT-304 in adults with advanced HER2-expressing solid tumors. The main questions it aims to answer are: * What is the safety profile of MT-304 when administered alone or with nivolumab? * What is the recommended Phase 2 dose (RP2D) of MT-304? Participants will: * Receive MT-304 alone (every 14 days) or with nivolumab (every 28 days). * Attend regular clinic visits for assessments and monitoring. * Continue treatment until disease progression, unacceptable toxicity, or study discontinuation.
This description comes directly from the study's public registry record.
Project Manager · +61731376255 · MTX-HER2-304_ClinicalStudy@novotech-cro.com
Clinical Department · +16174651022 · mt-304.clinical@createmedicines.com
Always discuss trial participation with your own doctor first.
| The Kinghorn Cancer Centre | Darlinghurst, New South Wales, Australia | Recruiting |
| Scientia Clinical Research Ltd | Randwick, New South Wales, Australia | Recruiting |
| Calvary Mater Newcastle | Waratah, New South Wales, Australia | Recruiting |
| Icon Cancer Centre South Brisbane | South Brisbane, Queensland, Australia | Recruiting |
| Cancer Research SA Pty Ltd | Adelaide, South Australia, Australia | Recruiting |
| Cabrini Health | Melbourne, Victoria, Australia | Recruiting |
| Linear Clinical Research | Nedlands, Western Australia, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07334119